The application of ivabradine in the management of ischaemic heart disease
Abstract
Ischemic heart disease is not only serious disorder with special clinical characteristics and generally requiring multidisciplinary approach, but also a social and economic problem now. Heart rate control is one of the main therapeutic principles that should be applied in patients with ischemic heart disease. In practice there are always cases when β-blockers for reducing heart rate should not be used because of contraindications in patients (for example, disorders of carbohydrate and lipid metabolism). Ivabradine can be an alternative in this situation due to selective and specific inhibition of the If-channels current across the cardiac pacemaker, characterized by negative chronotropism without negative inotropic effect and without affecting atrioventricular conduction and blood pressure. Ivabradine therapy is generally well tolerated and increases adherence commitment of patients to treatment. Raenom® (Gedeon Richter, Hungary) is generic ivabradine of good-quality.
About the Authors
M. A. Gurevich
M.F.Vladimirskiy Moscow Regional Clinical Institute
Russian Federation
Russian Federation
N. A. Kuzmenko
M.F.Vladimirskiy Moscow Regional Clinical Institute
Russian Federation
Russian Federation
References
1. Российский статистический ежегодник-2014, Федеральная служба государственной статистики. электронный ресурс: www.gks.ru
2. ESC guidelines on the management of stable coronary artery disease, 2013. Eur Heart J 2013; 34: 2949-3003.
3. Диагностика и лечение хронической ишемической болезни сердца. Клинические рекомендации МЗ РФ, 2013 г. http://cardioweb.ru/klinicheskie-rekomendatsii.
4. ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012; 60: e44-164.
5. Copie X, Hnatkova K, Staunton A et al. Predictive power of increased heart rate versus depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction. Results of a two - year follow - up study. J Am Coll Cardiol 1996; 27 (2): 270-6.
6. Diaz A, Bourassa M.G, Guertin M-C, Tardif J-C. Long - term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26 (10): 967-74.
7. Pocock S.J, Wang D, Pfeffer M.A et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006; 27 (1): 65-75.
8. Gillum R.F, Makuc D.M, Feldman J.J. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow - up Study. Am Heart J 1991; 121 (1): 172-7.
9. Castelli W.P, Levy D, Wilson P.W.F, Kannel W. Sudden death: The view from Framingham. The Prevention of Sudden Death. Ed. by JB Kostis, M Sanders. New York: E Wiley-Liss, 1990; p. 1-8.
10. Janssen I, Katzmarzyk P.T, Church T.S, Blair S.N. The Cooper Clinic Mortality Risk Index: clinical score sheet for men. Am J Prev Med 2005; 29 (3): 194-203.
11. Ерофеева С.Б., Манешина О.А. Место ивабрадина - первого If-ингибитора избирательного и специфического действия, в лечении сердечно - сосудистых заболевнаий. Качественная клиническая практика. 2006; 1: 10-22.
12. Fox K, Ford I, Steg P.G et al. Ivabradine for patients with stable coronary artery disease and left - ventricular systolic dysfunction (BEAUTIFUL): a randomised, double - blind, placebo - controlled trial. Lancet 2008; 372 (9641): 807-16.
13. Swedberg K, Komajda M, Bohm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo - controlled study. Lancet 2010; 376 (9744): 875-85.
14. Riccioni G. Ivabradine: recent and potential applications in clinical practice. Exp Opin Pharmacother 2011; 12 (3): 443-50.
15. Ulu N, Henning R.H, Goris M et al. Effects of ivabradine and metoprolol on cardiac angiogenesis and endothelial dysfunction in rats with heart failure. J Cardiovasc Pharmacol 2009; 53 (1): 9-17.
16. Milliez P, Messaoudi S, Nehme J et al. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am J Physiol Heart Circ Physiol 2009; 296 (2): H435-441.
17. Maczewski M, Mackiewicz U. Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post - infarction rat heart. Cardiovasc Res 2008; 79 (1): 42-51.
18. Colin P, Ghaleh B, Monnet X et al. Contributions of heart and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol 2003; 284: 676-82.
19. Vilaine J.P, Thollon C, Villeneuve N et al. Procoralan, a new selective If current inhibitor. Eur Heart J 2003; 5 (Suppl. G): 26-35.
20. Бубнова М.Г. Оптимизация терапии больного с ишемической болезнью сердца в клинической практике: доказанная эффективность селективного ингибитора If-каналов ивабрадина // CardioСоматика. 2013; 4 (2): 27-36.
21. Davis K, Dietrich E. Ivabradine (Corlanor) for Heart Failure. Am Fam Physician 2016; 93 (8): 682-4.
22. Weeda E.R, Nguyen E, White C.M. The Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease. Ann Pharmacother 2016 Feb 25. pii: 1060028016631571.
23. Foster J.L, Bobadilla R.V. Ivabradine, a novel medication for treatment of heart failure with reduced ejection fraction. J Am Assoc Nurse Pract 2016 May 24. DOI: 10.1002/2327-6924.12371.
24. Карпов Ю.А., Деев А.Д. Программа АЛЬТЕРНАТИВА - исследование АнтиангинаЛЬной эффекТивности и пЕРеносимости кораксаНА (ивабрадина) и оценка качесТва жИзни пациентоВ со стАбильной стенокардией: результаты эпидемиологического исследования. Кардиология. 2008; 5: 30-5.
25. Национальные рекомендации по диагностике и лечению стабильной стенокардии. Кардиоваскулярная терапия и профилактика. 2008; 7 (6) (Прил. 4).
26. Пономарева А.И., Компаниец О.Г., Линчак Р.М., Иванчура Г.С. Пульсурежающая фармакотерапия у пациентов с гипертонической болезнью и хронической сердечной недостаточностью: теория и проблемы применения в реальной клинической практике // Системные гипертензии. 2016; 1: 52-7.
27. Марцевич С.Ю., Кутишенко Н.П., Деев А.Д. Оригинальные препараты и дженерики в кардиологии. Можно ли решить проблему взаимозаменяемости. Вестн. Росздравнадзора. 2009; 4: 48-51.
28. Tрухан Д.И. Рациональная фармакотерапия в кардиологии сквозь призму коморбидности и лекарственной безопасности // Справочник поликлинического врача. 2015; 1: 26-31.
Review
For citations:
Gurevich M.A., Kuzmenko N.A. The application of ivabradine in the management of ischaemic heart disease. Systemic Hypertension. 2016;13(4):26-29. (In Russ.)
Views:
108
Email this article 